Aurinia Pharmaceuticals (AUPH) traded lower on Wednesday as RBC Capital Markets downgraded the stock, citing an uneven risk-reward profile after the biotech added over ~8% in the previous session in ...
Aurinia Pharmaceuticals Inc. (AUPH) received a recently updated rating from RBC Capital’s Douglas Miehm, who moved the stock to a “Sector Perform” designation o. This rating comes with a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback